ALBERT

All Library Books, journals and Electronic Records Telegrafenberg

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Amlodipine  (1)
  • Hypertension  (1)
  • 1
    ISSN: 1432-1041
    Keywords: Amlodipine ; Nifedipine ; Compliance ; slow release formulation ; hypertension ; therapeutic coverage
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Abstract To study patient compliance in hypertensive outpatients amlodipine (5 mg once daily) and slow release nifedipine (20 mg twice daily) were compared in an open, crossover study in general practices. Four methods of assessment for patient compliance (pill count, taking compliance, days with correct dosing, timing compliance) were used in both study arms. For the latter three assessment a special device, the medication event monitoring system, was used to record the time and date of each opening and closure of the container. The compliance of the 320 hypertensive patients with once-daily amlodipine was markedly superior to twice-daily slow release nifedipine. Therapeutic coverage was also significantly better for amlodipine in the hypertensive patients. Amlodipine was better tolerated than nifedipine slow release. Patient compliance and therapeutic coverage with the calcium antagonist amlodipine given once daily was superior to slow release nifedipine b. d. in hypertensive outpatients recruited in general practice. Statistical Unit: Léon Kaufmann, Marie-Paule Derde, Data Investigation Company Europe, Brussels Participating Investigators: D. Abbate, G. Armand, C.I. Authelet, J.L. Badot, J. Baeck, P. Baeck, P. Bastin, C.I. Bernard, P. Bernard, B. Beyssens, J. Bosly, P. Boudart, J. Bourdeaudhuy, W. Callens, L. Carolides, Y. Catry, E. Cerstelotte, F. Charlier, H. Charloteaux, J.M. Chaudron, L. Christiaen, G. Cornette, P. Cranskens, R. Creteur, N. De Cock, M. De Corte, A. De Vos, P. Defrance, P. Delhaye, G. Deneckere, M. Dobbeleir, A. Dufour, P. Dumont, L. D'Haen, H. D'Haenens, P. Eloy, P. Evrard, C. Fellemans, G. Geeraerts, L. Gielen, D. Grand, J. Grosjean, J. Guffens, R. Guillaume, R. Hacquaert, V. Hamoir, W. Hens, M. Hondeghem, M.C. Humblet-Koch, L. Leven, W. Janssens, L. Jeanfils, J. Jodogne, B. Jortay, W. Ketels, J.M. Krzesinski, E. Langendries, J. Lannoy, M. Leeman, J. Leire, P. Lempereur, L. Lenaerts, F. Lustman, R. Martens, Y. Maus, M. Meroueh, J.P. Meurant, P. Meurant, A. Michiels, E. Mievis, H. Moors, K. Naesens, P. Neels, J. Neven, W. Odeurs, W. Pardon, M. Peduzzi, J. Piette, D. Plessers, P. Putzeys, A. Quoidbach, A. Renaerts, G. Rits, M. Ruhwiedel, M. Salavracos, M. Seret, P. Sibille, M. Taziaux, J. Teucq, H. Therasse, F. Tihon, F. Vandenput, J. Van Elsen, J.P. Van Liefferinge, J. Van Neck, M. Van Pelt, T. Van Vlaenderen, G. Vandenbeylaardt, M. Vandewoude, F. Veldeman, D. Ven, F. Verbruggen, A. Vlaeminck, P. Werion, J. Westerlinck.
    Type of Medium: Electronic Resource
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Springer
    European journal of clinical pharmacology 49 (1995), S. 73-79 
    ISSN: 1432-1041
    Keywords: Postmarketing surveillance ; Ramipril ; Hypertension
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Abstract A prospective observational cohort study of the angiotensin inhibitor, ramipril, was undertaken in four countries within the European Community-Netherlands, United Kingdom, Germany and Belgium. A total of 10,377 consecutive patients with essential hypertension were recruited to the study with the aim of follow-up for one year. Overall 37% of doctors who agreed to participate in the study actually enrolled at least one patient. One third of the doctors who enrolled patients in the study entered two thirds of patients studied. Some 15% of participating males and 27% of females were aged over 70 years. Newly diagnosed hypertensives comprised 22% of the study cohort, the proportion being highest in UK and Netherlands, whereas 53% were established hypertensives of two or more years' duration, the proportion being highest in Germany and Belgium. There were substantial differences among the participating countries in the concurrent treatment these patients were receiving for hypertension, with two or more co-therapies being most frequent in Germany and Belgium. There were also substantial differences in co-therapies for concurrent diseases among the participating countries, reflecting both standard therapeutic practices in local areas and differences in marketing of drugs in the different countries. This report describes the initial findings of this multinational study and emphasises the need to consider several major potentially confounding variables in the analysis of the outcome events both in this study and in other collaborative observational international monitoring schemes for adverse drug reactions.
    Type of Medium: Electronic Resource
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...